Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlycoMimetics Inc.

www.glycomimetics.com

Latest From GlycoMimetics Inc.

Global Blood Therapeutics' Voxelotor On Track For 2020 Sickle Cell Shakeup

The company's NDA for voxelotor was accepted by the US FDA for priority review with action expected in February, setting up a showdown with Novartis.

Blood & Coagulation Disorders Drug Review

Sickle Blow For Pfizer’s Rivipansel At Phase III RESETs Expectations

After a long wait, the top-line data for Pfizer’s RESET study of the investigational treatment for sickle cell disease disappoint. Shares in rivipansel’s originator GlycoMimetics halved on the news.

Clinical Trials Companies

J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo

Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: AstraZeneca's net prices set to slide in 2019; biotechs ponder disasters from government shutdown; Denali moves into gene therapy; Sangamo clarifies partnering strategy; and Scrip talks to Allergan and Aptinyx about upcoming NMDA data releases.

Business Strategies Pricing Debate

J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo

Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: AstraZeneca's net prices set to slide in 2019; biotechs ponder disasters from government shutdown; Denali moves into gene therapy; Sangamo clarifies partnering strategy; and Scrip talks to Allergan and Aptinyx about upcoming NMDA data releases.

Business Strategies Pricing Debate
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlycoMimetics Inc.
  • Senior Management
  • Rachel K King, CEO
    Brian Hahn, CFO
    John Magnani, PhD, SVP, Research & CSO
    Armand Girard, VP, Corp. Dev.
    Eric Feldman, MD, VP, Clinical Dev.
  • Contact Info
  • GlycoMimetics Inc.
    Phone: (240) 243-1201
    9708 Medical Center Dr.
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register